These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 19843675

  • 1. Testosterone and biological characteristics of breast cancers in postmenopausal women.
    Secreto G, Venturelli E, Meneghini E, Greco M, Ferraris C, Gion M, Zancan M, Fabricio AS, Berrino F, Cavalleri A, Micheli A.
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2942-8. PubMed ID: 19843675
    [Abstract] [Full Text] [Related]

  • 2. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z, Gardi J, Nyári T, Földesi I, Hajnal-Papp R, Ormándi K, Lázár G, Thurzó L, Schally AV.
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [Abstract] [Full Text] [Related]

  • 3. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
    Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
    [Abstract] [Full Text] [Related]

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 5. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.
    J Natl Cancer Inst; 2004 Dec 15; 96(24):1856-65. PubMed ID: 15601642
    [Abstract] [Full Text] [Related]

  • 6. Serum sex hormones and breast cancer risk factors in postmenopausal women.
    Lamar CA, Dorgan JF, Longcope C, Stanczyk FZ, Falk RT, Stephenson HE.
    Cancer Epidemiol Biomarkers Prev; 2003 Apr 15; 12(4):380-3. PubMed ID: 12692114
    [Abstract] [Full Text] [Related]

  • 7. Circulating steroid hormone levels and risk of breast cancer for postmenopausal women.
    Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2010 Feb 15; 19(2):492-502. PubMed ID: 20086116
    [Abstract] [Full Text] [Related]

  • 8. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
    Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI.
    Cancer; 2005 Jun 01; 103(11):2241-51. PubMed ID: 15844176
    [Abstract] [Full Text] [Related]

  • 9. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L.
    Cancer; 2007 Jun 01; 109(11):2197-204. PubMed ID: 17450590
    [Abstract] [Full Text] [Related]

  • 10. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L.
    Cancer Epidemiol Biomarkers Prev; 2000 Jul 01; 9(7):681-7. PubMed ID: 10919738
    [Abstract] [Full Text] [Related]

  • 11. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
    Vandorpe T, Smeets A, Van Calster B, Van Hoorde K, Leunen K, Amant F, Moerman P, Deraedt K, Brouckaert O, Van Huffel S, Wildiers H, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2011 Jul 01; 128(2):429-35. PubMed ID: 21562708
    [Abstract] [Full Text] [Related]

  • 12. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 13. Biomarkers associated with breast cancer are associated with obesity.
    Sauter ER, Scott S, Hewett J, Kliethermes B, Ruhlen RL, Basarakodu K, de la Torre R.
    Cancer Detect Prev; 2008 Nov 20; 32(2):149-55. PubMed ID: 18639389
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen value as a marker in breast cancer.
    Narita D, Cimpean AM, Anghel A, Raica M.
    Neoplasma; 2006 Nov 20; 53(2):161-7. PubMed ID: 16575473
    [Abstract] [Full Text] [Related]

  • 15. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK, Col NF, Kuntz KM.
    Surgery; 1999 Sep 20; 126(3):568-76. PubMed ID: 10486611
    [Abstract] [Full Text] [Related]

  • 16. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 17. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
    Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE.
    Cancer Res; 2004 Sep 15; 64(18):6814-9. PubMed ID: 15375001
    [Abstract] [Full Text] [Related]

  • 18. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.
    J Clin Oncol; 2007 Oct 01; 25(28):4423-30. PubMed ID: 17906205
    [Abstract] [Full Text] [Related]

  • 19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.
    Breast Cancer Res Treat; 2007 Mar 01; 101(3):279-84. PubMed ID: 16835704
    [Abstract] [Full Text] [Related]

  • 20. [Proliferation index, axillary lymph node status, hormone receptors and age as prognostic factors in primary breast cancer].
    Kaufmann M, Klinga K, Kühn W, Abel U.
    Geburtshilfe Frauenheilkd; 1989 Feb 01; 49 Suppl 1():104-8. PubMed ID: 2703135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.